Unlimited

Authorized users

Can lend chapters, not whole ebooks

The challenge of CMC regulatory compliance for biopharmaceuticals / John Geigert.

Third edition.

9783030137540 (electronic book)
3030137546 (electronic book)
9783030137533

Cham, Switzerland : Springer, [2019]

English

1 online resource

10.1007/978-3-030-13

RS380 .G45 2019

615/.19

This book since first published in 2004 has been a major resource providing insights and practical guidance for the CMC teams to develop an acceptable cost-effective, risk-based CMC regulatory compliance strategy for biopharmaceuticals (recombinant proteins, monoclonal antibodies, genetically engineered viruses and genetically engineered human cells) from early clinical stage development through market approval. The third edition of this book provides added coverage for the biosimilars, antibody drug conjugates (ADCs), bispecific antibodies, genetically engineered viruses, and genetically engineered cells. This third edition of the book also addresses the heightened pressure on CMC regulatory compliance timelines due to the introduction of expedited clinical pathways moving the clinical development closer to a seamless phase process (e.g., FDA Breakthrough Therapy designation, CBER Regenerative Medicine Advanced Therapy (RMAT) designation, EMA Priority Medicines (PRIME) designation). The Challenge of CMC Regulatory Compliance for Biopharmaceuticals is essential, practical information for all pharmaceutical development scientists, Manufacturing and Quality Unit staff, Regulatory Affairs personnel, and senior management involved in the manufacture of biopharmaceuticals.

Includes bibliographical references and index.

Access limited to authorized users.

Description based on online resource; title from digital title page (viewed on June 25, 2019).

Online Resources > Ebooks
All Resources